Silas Inman

3 weeks ago | managedhealthcareexecutive.com | Silas Inman

Glucagon-like peptide 1 (GLP-1) treatment resulted in side effects that often required additional medications, increasing overall pharmacy use and costs among GLP-1 drugs compared with nonusers, according to a real-world claims analysis completed by Blue Cross Blue Shield Association (BCBSA) and Blue Health Intelligence (BHI) that was presented as a poster at the annual meeting of the Academy of Managed Care Pharmacy in Houston this week When excluding the costs of the GLP-1 drugs themselves,...

3 weeks ago | managedhealthcareexecutive.com | Silas Inman

The most used words to describe the treatment paradigm for patients with multiple myeloma were complicated and complex, according to a poll during a session on managing multiple myeloma at the annual meeting of the Academy of Managed Care Pharmacy (AMCP) in Houston. The complexity comes from a wealth of highly effective, multidrug regimens that have gained FDA approval in a relatively short amount of time.

1 month ago | targetedonc.com | Silas Inman

The remarkable intracranial efficacy of novel HER2-targeted therapies has established a new treatment paradigm, allowing oncologists to prioritize systemic therapies over local interventions for managing small, asymptomatic brain metastases in patients with metastatic breast cancer, noted Sara A.

1 month ago | targetedonc.com | Silas Inman

Multiple novel agents with diverse mechanisms of action are currently in development to overcome resistance to endocrine therapy (ET) and CDK4/6 inhibitors in hormone receptor–positive breast cancer. This ongoing research, highlighted in a session by Hope S. Rugo, MD, at the 42nd Annual Miami Breast Cancer Conference, aims to address the significant unmet clinical need in this patient population.1“We stand here at the brink of a precipice.

1 month ago | onclive.com | Silas Inman

Several promising new agents are currently in development across various mechanisms of action to address the unmet need resulting from resistance to the combination of endocrine therapy (ET) and CDK4/6 inhibition for patients with hormone receptor–positive breast cancer, according to a session by Hope S. Rugo, MD, at the 42nd Annual Miami Breast Cancer Conference.1“We stand here at the brink of a precipice. There’s going to be a whole lot of these drugs approved in the future.